FAPI PET/CT: will it end the hegemony of 18F-FDG in oncology?

RJ Hicks, PJ Roselt, KG Kallur, RW Tothill… - Journal of Nuclear …, 2021 - Soc Nuclear Med
For over 40 years, 18F-FDG has been the dominant PET tracer in neurology, cardiology,
inflammatory diseases, and, most particularly, oncology. Combined with the ability to …

Initial clinical experience with 90Y-FAPI-46 radioligand therapy for advanced-stage solid tumors: a case series of 9 patients

J Ferdinandus, PF Costa, L Kessler… - Journal of Nuclear …, 2022 - Soc Nuclear Med
Fibroblast activation protein (FAP) is overexpressed in several solid tumors and therefore
represents an attractive target for radiotheranostic applications. Recent investigations …

Impact of 68Ga-FAPI PET/CT on staging and oncologic management in a cohort of 226 patients with various cancers

SA Koerber, M Röhrich, L Walkenbach… - Journal of Nuclear …, 2023 - Soc Nuclear Med
Since the development of fibroblast activation protein–targeted radiopharmaceuticals, 68Ga-
fibroblast activation protein inhibitor (FAPI) PET/CT has been found to be suitable for …

Three-time-point PET analysis of 68Ga-FAPI-46 in a variety of cancers

M Naeimi, PL Choyke, K Dendl, Y Mori… - Journal of Nuclear …, 2023 - Soc Nuclear Med
A growing family of 68Ga-fibroblast activation protein inhibitor (FAPI) PET probes has shown
promise in imaging a variety of medical conditions. 68Ga-FAPI-46, in particular, has …

Acquisition Duration Optimization Using Visual Grading Regression in [68Ga] FAPI-46 PET Imaging of Oncologic Patients

T Nilsson, P Rasinski, Ö Smedby… - Journal of Nuclear …, 2024 - Soc Nuclear Med
Fibroblast activation protein is a promising target for oncologic molecular imaging with
radiolabeled fibroblast activation protein inhibitors (FAPI) in a large variety of cancers …